HYLORIS PHARMACEUTIC

HYL
Real-time Quote. Real-time  - 12/02 04:07:55 am
15.2EUR -0.33%
Income Statement Evolution
Annual Income Statement Data
Fiscal Period: December 2019 2020
Net sales1 0,090,95
EBITDA1 --11,9
Operating profit (EBIT)1 --8,00
Operating Margin --842%
Pre-Tax Profit (EBT)1 --6,00
Net income1 --6,00
Net margin --632%
EPS2 -1,49-1,71
Dividend per Share2 --
Announcement Date 06/16/2020-
Previous period Next period
1 EUR in Million
2 EUR
Finances - Leverage
Fiscal Period: December 2019 2020
Net Debt1 --
Net Cash position1 -48,0
Leverage (Debt / EBITDA) -4,03x
Free Cash Flow --
ROE (Net Profit / Equities) --
Shareholders' equity1 --
ROA (Net Profit / Asset) --
Assets1 --
Book Value Per Share2 -3,72
Cash Flow per Share --
Capex1 -1,00
Capex / Sales -105%
Announcement Date 06/16/2020-
Previous period Next period
1 EUR in Million
2 EUR
Financial Ratios
Size 2020e 2021e
Capitalization 394 M € -
Entreprise Value (EV) 346 M € 352 M €
Valuation 2020e 2021e
P/E ratio (Price / EPS) -8,92x -28,8x
Capitalization / Revenue 415x 149x
EV / Revenue 364x 131x
EV / EBITDA -29,1x -24,4x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 4,10x 8,71x
Profitability 2020e 2021e
Operating Margin (EBIT / Sales) -842% -498%
Operating Leverage (Delta EBIT / Delta Sales) - -
Net Margin (Net Profit / Revenue) -632% -491%
ROA (Net Profit / Asset) - -
ROE (Net Profit / Equities) - -
Rate of Dividend - -
Balance Sheet Analysis 2020e 2021e
CAPEX / Sales   105% 3,77%
Cash Flow / Sales - -
Capital Intensity (Assets / Sales) - -
Financial Leverage (Net Debt / EBITDA) - -
EPS & Dividend